Xconomy National

Archives

by in

Entry	Author	Date	Location
Genzyme, Veracyte Strike Deal to Market Thyroid Cancer Diagnostic	Luke Timmerman	01/20/12	San Francisco
Sanofi CEO Viehbacher on Stirring Innovation in the Era of R&D Cutbacks	Luke Timmerman	01/17/12	National
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments	Arlene Weintraub	01/11/12	New York
Inspiration Bio Founders and Execs Inspired by New Boston Headquarters	Arlene Weintraub	01/04/12	Boston
NanoString Nails Breast Cancer Study, Challenging Genomic Health	Luke Timmerman	12/08/11	Seattle
Aileron Expands Roche Deal, Agios Gets $78M, Genzyme MS Drug Advances, & More Boston-Area Life Sciences News	Erin Kutz	11/18/11	Boston
Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial	Arlene Weintraub	11/14/11	Boston
Best Buy Picks Up MindShift, Termeer Funds NanoString, Basho Adds $5M More, & More Boston-Area Deals News	Erin Kutz	11/09/11	Boston
NanoString Grabs $20M From GE, Former Genzyme CEO to Pursue Molecular Diagnostics	Luke Timmerman	11/07/11	Seattle
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News	Erin Kutz	10/28/11	Boston
Sanofi Names David Meeker New CEO of Genzyme, Will Report to Viehbacher	Luke Timmerman	10/24/11	Boston
PerkinElmer Acquires Caliper for $600M, VideoIQ Nabs $7.5M, MC10 Snags $2.5M, & More Boston-Area Deals News	Erin Kutz	09/14/11	Boston
Former Genzyme Boss Henri Termeer Gives $10M to MGH for Personalized Medicine	Luke Timmerman	09/13/11	Boston
On-Q-ity Founder and Genzyme Vet, Mara Aspinall, Moves to Roche’s Ventana Medical	Gregory T. Huang	08/02/11	Boston
Lotus Pioneers New Treatment for Rare and Disfiguring Disorder, Raises $26 Million From Third Rock	Arlene Weintraub	06/30/11	Boston
Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News	Erin Kutz	06/24/11	Boston
My 33 Months at Xconomy, a Nano-Memoir (of Sorts)	Ryan McBride	04/29/11	Boston
FDA Panel OKs Vertex Drug, Dyax Works With FivePrime, Genzyme Amends Anika Lawsuit, & More Boston-Area Life Sciences News	Erin Kutz	04/29/11	Boston
Bluebird Bio Snaps up $30M for Gene Therapies, Adds ARCH Venture to Syndicate	Ryan McBride	04/20/11	Boston
Aveo Adds Termeer to Board, Monsanto Partners With Atlas, Biogen Drug Meets Clinical Goal, & More Boston-Area Life Sciences News	Erin Kutz	04/15/11	Boston
Genzyme’s Termeer Joins Aveo Board	Ryan McBride	04/12/11	Boston
Zacharon Nabs $210M Deal With Pfizer to Tackle Orphan Diseases	Luke Timmerman	04/07/11	San Diego
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the First Quarter	Gregory T. Huang	03/31/11	Boston
Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation	Ryan McBride	03/23/11	Boston
Synageva Grabs $25M for Rare Diseases Drug Pipeline	Ryan McBride	03/21/11	Boston
Alnylam Settles One Lawsuit, Hit With Another; Living Proof Raises $16M, Tolerx/GSK Drug Fails to Meet Goal, & More Boston-Area Life Sciences News	Rebecca Zacks	03/18/11	Boston
Edimer, Third Rock’s Bet on Rare Diseases, Aims to Begin First Human Tests	Ryan McBride	03/15/11	Boston
Report: Fabry Patients Sue Genzyme and Mt. Sinai Medical School	Ryan McBride	03/11/11	Boston
Epizyme Nabs Eisai Deal, Termeer Could Make $221.2M From Genzyme Buyout, Gates Funds Nimbus, & More Boston-Area Life Sciences News	Erin Kutz	03/11/11	Boston
Targeted Genetics, Re-invented as AmpliPhi, Bets on Anti-Bacterials, Moves HQ to London	Luke Timmerman	03/09/11	Seattle
Page 1 of 12	next page »